Â鶹¸ßÇå

Bishoy M. Faltas, M.D.

Hematology/Oncology

Locations and Appointments

Insurances Accepted

Please contact the doctor's office to verify that your insurance is accepted.

*Indicates this doctor is no longer accepting new patients with this insurance plan.

  • HMO
  • Medicare
  • PPO
  • EPO/POS
  • CHP
  • Blue Access
  • Blue Connection
  • EPO
  • HMO
  • Mediblue (Senior)
  • PPO
  • CBP
  • Medicaid
  • Medicare
  • Freedom
  • Liberty
  • Medicare Advantage
  • Metro/Core/Charter
  • Community Plan
  • Medicare
  • HMO
  • Medicare
Personal Statement

My philosophy is simple: the patient comes first. As part of the Genitourinary Oncology Program at Â鶹¸ßÇå, I am committed to delivering the best care to my patients. Our world-class multidisciplinary team ensures that we treat the patient as a whole, not just the cancer. I am driven by the desire to improve therapy of urological malignancies by identifying the genetic “Achilles heel” of each patient’s cancer. Through my research, I am committed to developing “precision medicine” approaches and conducting clinical trials for treatment of bladder cancer and other genitourinary malignancies. 

Biographical Info

Dr. Bishoy Morris Faltas is an Associate Professor of Medicine and Attending in the Genitourinary Oncology Program in the Division of Hematology & Medical Oncology at Â鶹¸ßÇå. Dr. Faltas is the Chief Research Officer of the Caryl and Israel Englander Institute for Precision Medicine focusing on the application of genomic approaches to clinical trials by tailoring treatment based on the unique molecular profile of each patient’s cancer. 

Dr. Faltas completed his Hematology and Medical Oncology Fellowship at Â鶹¸ßÇå, as well as additional training through a research fellowship in the laboratory of Dr. Mark A. Rubin. During this time, he led studies of the clonal evolution and the neoantigenic structure of platinum-resistant bladder cancer. As a physician-scientist, Dr. Faltas's laboratory (https://faltaslab.weill.cornell.edu/) conducts research focusing on understanding the molecular profiles of metastatic platinum-resistant urothelial bladder cancer. His research focus is on the mechanisms of mutagenesis and drug resistance in bladder carcinoma, as well as immunogenomic studies of urological malignancies. By understanding the molecular changes that occur as urothelial cancer evolves under the effect of chemotherapy and metastatic spread, Dr. Faltas aims to identify potential drug targets for translation into therapeutic clinical trials.

Dr. Faltas is the recipient of several research awards, including the Scott-Wadler Fellow Research award and the Weill Department of Medicine Fellow Award in Research. He has also received the NIH/NCATS CTSC KL2 Scholar grant, the American Society of Clinical Oncology Conquer Cancer Foundation Young Investigator Award, the American Society of Clinical Investigation Young Physician-Scientist Award, the American Association for Cancer Research (AACR) NextGen Star award, the Society for Basic Urologic Research (SBUR) Young Investigator Award, the Department of Defense Career Development Award, the Irma T. Hirschl and Monique Weill-Caulier Research Award, and the prestigious R37 MERIT award from the National Cancer Institute.

Dr. Faltas has published several articles in peer-reviewed journals such as Nature, Nature Genetics, and Nature Communications. Additionally, he is a reviewer for several journals including Nature and Nature Communications, and a member of several grant Review Committees. Dr. Faltas is a member of the editorial board of the ASCO Post. He also served as an Associate Scientific Advisor for the journal Science Translational Medicine.

Honors and Awards

2024

 

2023

 

2022

Irma T. Hirschl and Monique Weill-Caulier Research Award

Society for Basic Urology Research (SBUR) Young Investigator Award

Young Physician-Scientist Award, The American Society for Clinical Investigation (ASCI)

2019

Gellert Family-John P. Leonard, MD Research Scholar in Hematology and Medical Oncology

2017

NextGen Star, American Association for Cancer Research (AACR) annual meeting

2015, 2016

 

Merit Award to present at the American Society of Clinical Oncology (ASCO) annual Genitourinary symposium, and ASCO Annual Meetings, Conquer Cancer Foundation of ASCO

2016

Pre-Career Award Funding, Weill Department of Medicine, Â鶹¸ßÇå

2015

American Society of Clinical Oncology (ASCO) Young Investigator Award, Conquer Cancer Foundation of ASCO

2014-15

Scott Wadler Memorial Fellow Research Award, given annually to the fellow with the highest research productivity, Â鶹¸ßÇå (received the award in two successive years

2015

First place, Weill Department of Medicine Fellows' Research Award Competition, Â鶹¸ßÇå

2014

Award to attend the Annual AACR Workshop: Molecular Biology in Clinical Oncology, American Association for Cancer Research

2013

Award to attend ASCO-AACR Methods in Clinical Oncology Workshop, American Society of Clinical Oncology, and American Association for Cancer Research

Board Certifications
American Board of Internal Medicine
American Board of Internal Medicine (Medical Oncology)
Clinical Expertise
Bladder Cancer
Cancer of Ureter
Urethral Cancer
Prostate Cancer
Kidney Cancer
Immunotherapy
Genomics
Languages
English
Research
Education 
  • M.B.,B.S.
    College of Medicine Assiut (Egypt)
    2005
Appointments 
  • Gellert Family-John P. Leonard, M.D. Research Scholar
    Weill Cornell Medical College, Cornell University
  • Associate Attending Physician
    NewYork-Presbyterian Hospital
  • Associate Professor of Medicine
    Weill Cornell Medical College, Cornell University
  • Associate Professor of Cell and Developmental Biology
    Weill Cornell Medical College, Cornell University
Videos

Bishoy Faltas, MD

Relationships and collaborations with for-profit and not-for profit organizations are of vital importance to our faculty because these exchanges of scientific information foster innovation. As experts in their fields, WCM physicians and scientists are sought after by many organizations to consult and educate. WCM and its faculty make this information available to the public, thus creating a transparent environment.

Professional Services: 
UroToday
Other Interest: 
Guardant Health, Inc.